The rise of a grey market in India, where unsupervised doses are sold at exorbitant rates, demonstrates that excessive control merely drives patients underground. Regulation should protect safety, not ...

Unregulated compounded GLP-1s are not the same as the legitimate medications that doctors prescribe for weight loss and ...

Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes ...

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant.

Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...

Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

Two years later, those treatments have thrust Metsera to the centre of a fierce takeover battle, with Ozempic maker Novo Nordisk and Pfizer willing to pay up to $10bn for the company. Both once again ...

Viccy Gibson paid just £70 for a month's supply of what she was told was semaglutide - the same ingredient used in ...